natgillin/translations-raw huggingface dataset:
The vaccine is used to prevent viraemia (the presence of viruses in the blood) in sheep and to limit viraemia in cattle. 
Cepivo se uporablja za preprečitev viremije (prisotnosti virusa v krvi) pri ovcah in omejitev viremije pri govedu.
The risk of bluetongue transmission to cattle following vaccination with Bovilis BTV8 was further investigated in two epidemiological models. 
Tveganje prenosa okužbe z virusom modrega jezika pri govedu po opravljenem cepljenju s cepivom Bovilis BTV8 so nadalje raziskali v dveh epidemioloških modelih.
Inactivated adjuvanted vaccine against bluetongue virus serotype 8 
inaktivirano adjuvantno cepivo proti virusu bolezni modrikastega jezika, serotip 8
The efficacy of the vaccine in cattle and sheep was studied in a number of laboratory trials; in cattle from six weeks of age and in sheep from one month of age.. 
Učinkovitost cepiva pri govedu in ovcah so proučili v številnih laboratorijskih preskušanjih, in sicer so cepivo uporabili pri govedu, starejšemu od šest tednov, in ovcah, starejših od enega meseca.
The withdrawal period for both sheep and cattle for meat and milk is zero days. 
Karenca za meso in mleko pri ovcah in govedu je nič dni.
The CVMP concluded that the benefits of Bovilis BTV8 exceed the risks and recommended that Bovilis BTV8 be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Bovilis BTV8 večje od z njim povezanih tveganj, in priporočil, da se za zdravilo Bovilis BTV8 izda dovoljenje za promet.
The European Commission granted a marketing authorisation valid throughout the European Union, for Bovilis BTV8 on 06/09/2010. 
Evropska komisija je dovoljenje za promet z zdravilom Bovilis BTV8, veljavno po vsej Evropski uniji, odobrila 6. septembra 2010.
The safety of the vaccine was studied in laboratory safety studies carried out with an overdose of Bovilis BTV8 in young lambs and calves and in pregnant ewes and cows. 
Varnost cepiva so proučili v laboratorijskih študijah varnosti, ki so jih opravili z uporabo čezmernih odmerkov cepiva Bovilis BTV8 pri jagnjetih in teletih ter brejih ovcah in kravah.
Bovilis BTV8 is a vaccine. 
Zdravilo Bovilis BTV8 je cepivo.
The first injection is given from one month of age in sheep and from six weeks of age in cattle. 
Prva injekcija se da vsaj en mesec starim ovcam in vsaj šest tednov staremu govedu.
There can also be a temporary swelling at the injection site, lasting for up to three weeks in sheep and six weeks in cattle. 
Na mestu injiciranja se lahko pojavi prehodna oteklina, ki izgine v največ treh tednih pri ovcah in največ šest tednih pri govedu.
Bovilis BTV8 contains bluetongue virus that has been inactivated so that it cannot cause the disease. 
Zdravilo Bovilis BTV8 vsebuje viruse modrega jezika, ki so inaktivirani in zato ne morejo povzročiti bolezni.
The studies showed that the vaccine is safe for both sheep and cattle and that it prevents viraemia in sheep from one month of age when infected with bluetongue virus serotype 8, whereas Bovilis BTV8 reduces viraemia in cattle from six weeks of age. 
Študije so pokazale, da je cepivo Bovilis BTV 8 varno za ovce in govedo ter da preprečuje viremijo pri ovcah, ki so stare vsaj en mesec in so okužene z virusom modrega jezika, serotip 8, zmanjša pa tudi viremijo pri govedu, starejšemu od šest tednov.
Bovilis BTV8 was shown to be safe for use in pregnant ewes and cattle. 
Dokazano je bilo, da se lahko cepivo Bovilis BTV8 varno uporablja pri brejih ovcah in govedu.
Other information about Bovilis BTV8: 
Druge informacije o zdravilu Bovilis BTV8:
What benefit has Bovilis BTV8 shown during the studies? 
Kakšne koristi je zdravilo Bovilis BTV8 izkazalo med študijami?
Bovilis BTV8 is used in cattle and sheep to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges. 
Zdravilo Bovilis BTV8 se uporablja pri govedu in ovcah za zaščito pred boleznijo modrega jezika, tj. okužbo, ki jo povzroča virus modrega jezika, ki ga prenašajo krvosesi insekti.
Bovilis BTV8 is a vaccine that contains an inactivated (killed) bluetongue serotype 8 virus as the active substance. 
Bovilis BTV8 je cepivo, ki kot zdravilno učinkovino vsebuje inaktiviran (uničen) virus bolezni modrikastega jezika, serotip 8.
What is the risk associated with Bovilis BTV8? 
Kakšna tveganja so povezana z zdravilom Bovilis BTV8?
The virus exists in several forms (serotypes) throughout the world; the type used in Bovilis BTV8 is serotype 8. 
Virus obstaja v različnih oblikah (serotipih) po vsem svetu.
Why has Bovilis BTV8 been approved? 
Zakaj je bilo zdravilo Bovilis BTV8 odobreno?
How has Bovilis BTV8 been studied? 
Kako je bilo zdravilo Bovilis BTV8 raziskano?
What is Bovilis BTV8 used for? 
Za kaj se zdravilo Bovilis BTV8 uporablja?
What is Bovilis BTV8? 
Kaj je zdravilo Bovilis BTV8?
How does Bovilis BTV8 work? 
Kako zdravilo Bovilis BTV8 deluje?
This summary was last updated in 02-2018. 
Povzetek je bil nazadnje posodobljen 02-2018.
It is given by injection under the skin, once a day. 
Injicira se pod kožo enkrat dnevno.
The diagnosis must be confirmed by genetic testing. 
Diagnoza mora biti potrjena z genetskim testiranjem.
• do not grow normally because they do not have enough growth hormone; 
• ne rastejo normalno, ker nimajo dovolj rastnega hormona;
These side effects are uncommon in children (may affect between 1 and 10 patients in 1,000). 
Ti neželeni učinki so pri otrocih občasni (lahko se pojavijo pri 1 do 10 bolnikov od 1 000).
It must also not be used for promoting growth in children with closed epiphyses (when the large bones have finished growing). 
Prav tako se ne sme uporabljati za pospeševanje rasti otrok z zaprtimi epifizami (ko so velike kosti prenehale rasti).
The European Commission granted a marketing authorisation valid throughout the European Union for Omnitrope on 12 April 2006. 
Evropska komisija je dovoljenje za promet z zdravilom Omnitrope, veljavno po vsej Evropski uniji, izdala 12. aprila 2006.
The deficiency can have started in adulthood or childhood, and needs to be confirmed by testing before treatment. 
Pomanjkanje se lahko začne v odrasli dobi ali v otroštvu in ga je pred zdravljenjem treba potrditi s testiranjem.
• have a genetic condition called Prader-Willi syndrome. 
• imajo genetsko bolezen, imenovano Prader-Willijev sindrom.
Children receiving Omnitrope and Genotropin grew at a similar rate of about 10.7 cm per year. 
Otroci, ki so prejemali zdravilo Omnitrope ali Genotropin, so zrasli podobno hitro za približno 10,7 cm na leto.
The full EPAR for Omnitrope can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Omnitrope je na voljo na spletni strani agencije: website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The dose may need to be adjusted over time, depending on change in body weight and response to treatment. 
Morda bo treba sčasoma prilagoditi odmerek, odvisno od spremembe telesne mase in odziva na zdravljenje.
• are short because they have long-term kidney disease or a genetic disorder called Turner syndrome; 
• so premajhne rasti, ker imajo dolgotrajno bolezen ledvic ali genetsko motnjo, imenovano Turnerjev sindrom;
Omnitrope is given to improve their growth and body composition (by reducing fat and improving muscle mass). 
Zdravilo Omnitrope se daje za izboljšanje rasti in sestave telesa (z zmanjšanjem maščobe in izboljšanjem mišične mase).
In adults, side effects related to fluid retention, such as peripheral oedema (swelling, especially of the ankles and feet), paraesthesia (numbness or tingling), joint and muscle pain, and stiffness of the limbs are common (may affect between 1 and 10 patients in 100). 
Pri odraslih so neželeni učinki, ki so povezani z zastajanjem tekočine v telesu in se kažejo kot periferni edem (otekanje, zlasti gležnjev in nog), parestezija (odrevenelost ali mravljinčenje), bolečine v sklepih in mišicah ter okorelost okončin, pogosti (lahko se pojavijo pri 1 do 10 bolnikov od 100).
This means that Omnitrope is highly similar to a biological medicine (the ‘reference medicine') that is already authorised in the EU. 
To pomeni, da je zelo podobno biološkemu zdravilu (t. i. „referenčnemu zdravilu“), ki je že odobreno v Evropski uniji (EU).
This is a summary of the European public assessment report (EPAR) for Omnitrope. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Omnitrope.
As with all protein medicines, some patients may develop antibodies (proteins that are produced in response to Omnitrope). 
Kot pri vseh zdravilih, ki vsebujejo beljakovine, se lahko pri nekaterih bolnikih pojavijo protitelesa (beljakovine, ki se tvorijo kot odziv na zdravilo Omnitrope).
It is important for growth during childhood and adolescence, and it also affects how the body handles proteins, fat and carbohydrates. 
Pomemben je za rast v otroštvu in adolescenci, vpliva pa tudi na presnovo beljakovin, maščob in ogljikovih hidratov v telesu.
What measures are being taken to ensure the safe use of Omnitrope? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Omnitrope?
Omnitrope is a medicine used to treat children who: 
Zdravilo Omnitrope se uporablja za zdravljenje otrok, ki:
What is Omnitrope and what is it used for? 
Kaj je zdravilo Omnitrope in za kaj se uporablja?
The European Medicines Agency considered that, in accordance with EU requirements for biosimilar medicines, Omnitrope has been shown to have a comparable quality, safety and effectiveness to Genotropin. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Omnitrope po kakovosti, varnosti in učinkovitosti primerljivo zdravilu Genotropin.
• are short and were born small for their gestational age, and have not caught up by the age of 
• so premajhne rasti in so se rodili majhni za svojo gestacijsko starost ter do starosti 4 let ali več niso nadomestili zaostanka;
Somatropin is produced by a method known as ‘recombinant DNA technology': the hormone is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce somatropin. 
Proizvaja se z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri hormon tvorijo bakterije, ki so prejele gen (DNK), kar jim omogoča tvorjenje somatropina.
Results showed that, after treatment for 9 months, Omnitrope was as effective as Genotropin in improving growth. 
Rezultati so pokazali, da je bilo po 9-mesečnem zdravljenju zdravilo Omnitrope enako učinkovito kot zdravilo Genotropin pri izboljšanju rasti.
Other information about Omnitrope 
Druge informacije o zdravilu Omnitrope
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Omnitrope have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Omnitrope upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Omnitrope was compared with Genotropin in 89 children with a lack of growth hormone who had not been treated before. 
Zdravilo Omnitrope so primerjali z zdravilom Genotropin pri 89 otrocih s pomanjkanjem rastnega hormona, ki predhodno še niso bili zdravljeni.
For more information about treatment with Omnitrope, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Omnitrope preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What benefits of Omnitrope have been shown in studies? 
Kakšne koristi je zdravilo Omnitrope izkazalo v študijah?
The patient or caregiver can inject Omnitrope, after being trained by a doctor or a nurse. 
Bolnik ali negovalec lahko zdravilo Omnitrope injicirata sama, potem ko sta ju za to usposobila zdravnik ali medicinska sestra.
What are the risks associated with Omnitrope? 
Kakšna tveganja so povezana z zdravilom Omnitrope?
Omnitrope must not be used if the patient has an active tumour or an acute life-threatening illness. 
Zdravilo Omnitrope se ne sme uporabljati pri bolnikih, ki imajo aktiven tumor ali akutno smrtno nevarno bolezen.
The doctor calculates the dose for each patient individually according to the body weight and the condition being treated. 
Zdravnik izračuna odmerek za vsakega bolnika posebej glede na njegovo telesno maso in bolezen, zaradi katere se zdravi.
The active substance in Omnitrope, somatropin, is identical to the human growth hormone, which it replaces. 
Zdravilna učinkovina v zdravilu Omnitrope, somatropin, je enaka človeškemu rastnemu hormonu, ki ga nadomešča.
Omnitrope is also used as replacement therapy in adult patients with pronounced growth hormone deficiency. 
Zdravilo Omnitrope se uporablja tudi kot nadomestno zdravljenje pri odraslih bolnikih z izrazitim pomanjkanjem rastnega hormona.
For practical information about using Omnitrope, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Omnitrope naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
It is not intended to provide practical advice on how to use Omnitrope. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The medicine is available as a powder and solvent, which are made up into a solution for injection, or as a ready-to-use solution in a cartridge. 
Zdravilo je na voljo v obliki praška in vehikla za pripravo raztopine za injiciranje ali v obliki pripravljene raztopine v vložku.
Why is Omnitrope approved? 
Zakaj je bilo zdravilo Omnitrope odobreno?
Omnitrope can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with growth disorders. 
Predpisovanje in izdaja zdravila Omnitrope je le na recept, zdravljenje z njim pa mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem bolnikov z motnjami rasti.
The reference medicine for Omnitrope is Genotropin. 
Referenčno zdravilo za zdravilo Omnitrope je zdravilo Genotropin.
Omnitrope was studied to show that it is comparable to the reference medicine, Genotropin. 
Zdravilo Omnitrope so proučevali, da bi dokazali, ali je primerljivo z referenčnim zdravilom Genotropin.
Omnitrope contains the active substance somatropin and is a ‘biosimilar' medicine. 
Zdravilo Omnitrope vsebuje zdravilno učinkovino somatropin in je „podobno biološko zdravilo“.
The Omnitrope cartridges should only be used with the special Omnitrope injection device. 
Zdravilo Omnitrope v obliki vložkov se lahko uporablja samo s posebno pripravo za injiciranje zdravila Omnitrope.
For the full list of side effects of Omnitrope, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Omnitrope, glejte navodilo za uporabo.
How is Omnitrope used? 
Kako se zdravilo Omnitrope uporablja?
Growth hormone is released by the pituitary gland (a gland at the base of the brain). 
Rastni hormon izloča hipofiza (žleza v možganskem dnu).
Therefore, the Agency's view was that, as for Genotropin, the benefit outweighs the identified risk and it recommended that Omnitrope be given marketing authorisation. 
Zato je menila, da njegove koristi enako kot pri zdravilu Genotropin odtehtajo znana tveganja.
How does Omnitrope work? 
Kako zdravilo Omnitrope deluje?
Howeve,r these antibodies do not have an effect on how well Omnitrope works. 
Vendar pa ta ne vplivajo na to, kako dobro deluje zdravilo Omnitrope.
LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH
100mg/cap Capsule, soft 
100mg/cap kapsula, mehka peroralna uporaba
50mg/cap Capsule, soft 
50mg/cap kapsula, mehka peroralna uporaba
25mg/cap Capsule, soft 
25mg/cap kapsula, mehka peroralna uporaba
500mg/5ml Oral solution 
500mg/5ml peroralna raztopina peroralna uporaba 100 mg/ml
21 March 2014 
21. marec 2014
The Committee appointed C. Ibrahim as rapporteur and H. Jukes as co-rapporteur. 
Odbor je za poročevalko imenoval C. Ibrahim, za soporočevalko pa H. Jukes.
The United Kingdom is the reference Member State and Germany and the Netherlands are concerned Member States. 
Referenčna država članica je Združeno kraljestvo, zadevni državi članici pa sta Nemčija in Nizozemska.
International non-proprietary name (INN): eprinomectin 
Mednarodno nelastniško ime (INN): eprinomektin
The opinion was converted into a Decision by the European Commission on 21 March 2014. 
Mnenje je bilo spremenjeno v sklep Evropske komisije dne 21. marca 2014.
The decentralised procedure started on 21 February 2012. 
Decentralizirani postopek se je začel 21. februarja 2012.
Written explanations were provided by the applicant on 19 November 
Predlagatelj je 19. novembra 2013 podal pisna pojasnila.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the summary of product characteristics and package leaflet in Annex III. 
Seznam zadevnih imen zdravila je v Prilogi I. Znanstveni zaključki so podani v Prilogi II, skupaj s povzetkom glavnih značilnosti zdravila in navodilom za uporabo v Prilogi III.
Potential serious risks were identified during the decentralised procedure by Germany regarding the environmental safety of the product. 
Med decentraliziranim postopkom je Nemčija ugotovila možnost resnega tveganja, povezanega z varnostjo zdravila za okolje.
Day 60 of the CMD(v) procedure was on 18 April 2013, and since the Member States concerned failed to reach an agreement regarding the product the procedure was referred to the CVMP. 
Šestdeseti dan postopka skupine CMD(v) je bil 18. april 2013 in ker zadevne države članice niso uspele doseči soglasja v zvezi z zdravilom, je bil postopek napoten na odbor CVMP.
On 26 April 2013, the reference Member State, the United Kingdom, notified the Agency that the CMD(v) had failed to reach an agreement regarding the product and referred the matter to the CVMP pursuant to Article 33(4) of Directive 2001/82/EC. 
Referenčna država članica, Združeno kraljestvo, je 26. aprila 2013 obvestila agencijo, da skupina CMD(v) ni dosegla soglasja v zvezi z zdravilom, in zadevo napotila na odbor CVMP, skladno s členom 33(4) Direktive 2001/82/ES.
Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle contains eprinomectin as an active substance and is intended for use in cattle as a topical application for the treatment and control of infections from gastrointestinal roundworms (adults and fourth stage larvae), lungworms (adults and fourth stage larvae), warbles (parasitic stages), mange mites, lice and horn flies. 
Zdravilo Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka, vsebuje zdravilno učinkovino eprinomektin in je namenjeno za lokalno uporabo pri govedu za zdravljenje in nadzorovanje okužb z želodčno-črevesnimi glistami (odraslimi in ličinkami v četrti fazi razvoja), pljučnimi črvi (odraslimi in ličinkami v četrti fazi razvoja), govejimi zolji (v parazitskem stadiju), garjami, ušmi in muhami Haematobia irritans.
On day 210, these issues remained unsolved and therefore a referral under Article 33(1) of Directive 2001/82/EC to the Coordination group for Mutual recognition and Decentralised procedures (veterinary) (CMD(v)) was started on 18 February 2013. 
Ker ti pomisleki na 210. dan še vedno niso bili rešeni, je bila zadeva 18. februarja 2013 v skladu s členom 33(1) Direktive 2001/82/ES napotena na Usklajevalno skupino za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v veterinarski medicini (CMD(v)).
Therefore, the Committee adopted by consensus a positive opinion on 15 January 2014 recommending the granting of the marketing authorisations for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle with amendment to the summary of product characteristics and package leaflet of the reference Member State. 
Odbor je zato 15. januarja 2014 soglasno sprejel pozitivno mnenje in priporočil odobritev dovoljenja za promet z zdravilom Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka, skupaj s spremembo povzetka glavnih značilnosti zdravila in navodila za uporabo referenčne države članice.
This is a ‘hybrid' application according to Article 13(3) of Directive 2001/82/EC, as amended, referring to the reference product Eprinex PourOn Solution for Beef and Dairy Cattle. 
Vloga je v skladu s členom 13(3) Direktive 2001/82/ES, kakor je bila spremenjena, „hibridna vloga“, ki se nanaša na referenčno zdravilo Eprinex kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka.
Based on the evaluation of the currently available data, the CVMP considered that the benefit-risk profile of Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle is positive. 
Na podlagi ocene trenutno razpoložljivih podatkov je odbor CVMP menil, da je razmerje med tveganji in koristmi za zdravilo Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka, pozitivno.
The applicant, Norbrook Laboratories Ltd, submitted an application for a decentralised procedure for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle. 
Predlagatelj, družba Norbrook Laboratories Ltd, je predložil vlogo za decentralizirani postopek za zdravilo Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka.
Opinion following an Article 33(4)0F referral for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle 
Mnenje v zvezi z napotitvijo v skladu s členom 33(4)0F za zdravilo Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka EMA/128538/2014
Such data should be submitted to the Agency together with the periodic safety update reports. 
Te rezultate je treba predložiti Agenciji skupaj z rednimi posodobljenimi poročili o varnosti.
It can cause: 
Povzroči lahko:
Reversal should occur rapidly within 1-2 minutes. 
Reverzija mora nastopiti hitro v 1-2 minutah.
• Your dog to feel cold when touched (for example the ears). 
• Pes je hladen na dotik (npr. na ušesih).
MARKETING AUTHORISATION NUMBER(S) EU/2/11/127/001 
ŠTEVILKA DOVOLJENJA ZA PROMET EU/2/11/127/001
3.0 to 4.2 4.3 to 6.1 6.2 to 8.0 8.1 to 9.9 10.0 to 11.7 11.8 to 13.6 13.7 to 15.5 15.6 to 17.4 17.5 to 19.3 19.4 to 21.2 21.3 to 23.1 23.2 to 25.0 25.1 to 26.9 27.0 to 28.8 28.9 to 30.6 30.7 to 32.5 32.6 to 34.4 34.5 to 36.3 36.4 to 38.2 38.3 to 40.1 40.2 to 42.0 42.1 to 43.9 44.0 to 45.8 45.9 to 47.7 47.8 to 49.6 49.7 to 51.4 51.5 to 53.3 53.4 to 55.2 55.3 to 57.0 
4,3 do 6,1 6,2 do 8,0 8,1 do 9,9 10,0 do 11,7 11,8 do 13,6 13,7 do 15,5 15,6 do 17,4 17,5 do 19,3 19,4 do 21,2 21,3 do 23,1 23,2 do 25,0 25,1 do 26,9 27,0 do 28,8 28,9 do 30,6 30,7 do 32,5 32,6 do 34,4 34,5 do 36,3 36,4 do 38,2 38,3 do 40,1 40,2 do 42,0 42,1 do 43,9 44,0 do 45,8 45,9 do 47,7 47,8 do 49,6 49,7 do 51,4 51,5 do 53,3 53,4 do 55,2 55,3 do 57,0
The unbroached vial does not require any special storage conditions. 
Neodprta viala ne zahteva posebnih pogojev shranjevanja.
The systemic bioavailability of the veterinary medicinal product is approximately 40%. 
Sistemska biološka razpoložljivost zdravila je približno 40 %.
Your veterinarian can best describe these for you. 
Najbolje jih lahko opiše vaš veterinar.
• Loss of appetite or drinking less water. 
• Izgubo teka ali pitje manj vode.
For transdermal use. 
Za transdermalno uporabo.
Recuvyra should only be used for dogs. 
Recuvyra se sme uporabljati samo za pse.
Recuvyra like any other medicine may cause adverse reactions. 
Recuvyra lahko kot vsako drugo zdravilo povzroča neželene učinke.
Bodyweight (kilograms) 
Telesna teža (kilogrami)
Your dog should not be given Recuvyra if it: 
Psu se ne sme dati Recuvyre, če: